Patents Assigned to Xyra, LLC
  • Patent number: 12551706
    Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.
    Type: Grant
    Filed: March 27, 2024
    Date of Patent: February 17, 2026
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Patent number: 12257228
    Abstract: Disclosed are cardioversion methods for patients with either paroxysmal or persistent AFib which methods use budiodarone or a pharmaceutical composition comprising budiodarone.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: March 25, 2025
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Publication number: 20250009708
    Abstract: Disclosed are cardioversion methods for patients with either paroxysmal or persistent AFib which methods use budiodarone or a pharmaceutical composition comprising budiodarone.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 9, 2025
    Applicant: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Patent number: 12115373
    Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: October 15, 2024
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Patent number: 11975202
    Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: May 7, 2024
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Patent number: 11839768
    Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: December 12, 2023
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner
  • Patent number: 11759640
    Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: September 19, 2023
    Assignee: Xyra, LLC
    Inventors: Pascal Druzgala, Peter Gerard Milner